Building a deep pipeline, Taligen is rapidly advancing multiple clinical candidates.

Taligen’s lead therapeutic candidates are recombinant fusion proteins and monoclonal antibodies that target key factors, known as Factors B and H, in the complement amplification loop, which the company’s founders have validated as fundamental to excessive inflammation in many important diseases.

Taligen’s initial compounds are focused on orphan diseases, age-related macular degeneration (AMD), and severe inflammatory diseases.